Takeda’s top priority is the health of Canadians. Their well-being is central to our work and drives our commitment to deliver a diverse portfolio of innovative treatments.
Current important medicines available to Canadians from Takeda Canada include:
For legacy Shire product information, please visit
https://www.takeda.com/en-ca/what-we-do/our-medicines/shire-products
PRODUCTS |
|
ADDERALL XR® mixed salts amphetamine |
|
ADVATE® Antihemophilic Factor (Recombinant) |
|
ADYNOVATE® Antihemophilic Factor (Recombinant), PEGylated |
|
AGRYLIN® anagrelide hydrochloride |
|
ALUNBRIG® brigatinib |
|
ANTITHROMBIN III NF® Antithrombin III (Human) |
|
CINRYZE® C1 inhibitor [human] |
|
CUVITRU® Normal Immunoglobulin (Human) |
|
DEXILANT® dexlansoprazole |
Product Monograph |
ELAPRASE® idursulfase for injection |
Product Monograph |
ENTYVIO® vedolizumab |
Product Monograph |
FEIBA® NF Anti-Inhibitor Coagulant Complex |
Product Monograph |
FIRAZYR® icatibant injection |
Product Monograph |
FOSRENOL® lanthanum carbonate hydrate |
Product Monograph |
FRUZAQLATM fruquintinib |
Product Monograph |
GAMMAGARD LIQUID® Immunoglobulin Intravenous (Human) |
Product Monograph |
GAMMAGARD® S/D Immunoglobulin Intravenous (Human) [IGIV] |
Product Monograph |
GLASSIA® Alpha-1 Proteinase Inhibitor (Human) Injection |
Product Monograph |
HyQvia® Normal Immunoglobulin (Human) and Recombinant Human Hyaluronidase |
Product Monograph |
ICLUSIG® Ponatinib Tablets |
|
IMMUNINE® VH Factor IX Concentrate (Human) |
Product Monograph |
INTUNIV XR® guanfacine hydrochloride |
Product Monograph |
KAZANO® alogliptin (as alogliptin benzoate) and metformin hydrochloride |
Product Monograph |
LIVTENCITY® maribavir tablets |
Product Monograph |
MEZAVANT® mesalamine |
Product Monograph |
NESINA® alogliptin (as alogliptin benzoate) |
Product Monograph |
NINLARO® ixazomib (as ixazomib citrate) |
Product Monograph |
OBIZUR® Antihemophilic Factor (Recombinant), Porcine Sequence |
Product Monograph |
ONDISSOLVE® ODF ondansetron |
Product Monograph |
PANTOLOC® pantoprazole sodium |
Product Monograph |
REPLAGAL® agalsidase alfa for injection |
Product Monograph |
REVESTIVE® Teduglutide for injection |
Product Monograph |
RIXUBIS® Recombinant Coagulation Factor IX (rFIX), Nonacog gamma for Injection |
Product Monograph |
TAKHZYRO® lanadelumab injection |
Product Monograph |
TECTA® pantoprazole magnesium |
Product Monograph |
VONVENDI® Lyophilized Powder for Solution |
Product Monograph |
VPRIV® velaglucerase alfa |
Product Monograph |
VYVANSE® lisdexamfetamine dimesylate |
Product Monograph |
ADDERALL XR® and ADDERALL® are registered trademarks of Takeda Pharmaceuticals U.S.A., Inc.
ADYNOVATE® is a registered trademark of Baxalta Incorporated.
ALUNBRIG® and the ALUNBRIG Logo® are registered trademarks of ARIAD Pharmaceuticals, Inc.
CINRYZE® and the CINRYZE Logo are registered trademarks of ViroPharma Biologics LLC, a Takeda company.
CUVITRU® is a registered trademark of Baxalta Incorporated.
DEXILANT® is a trademark of Takeda Pharmaceuticals U.S.A., Inc and used under licence by Takeda Canada Inc.
ELAPRASE® and the ELAPRASE Logo® are registered trademarks of Shire Human Genetic Therapies, Inc.
ENTYVIO® is a registered trademark of Millennium Pharmaceuticals, Inc. and used under licence by Takeda Canada Inc.
FEIBA® is a registered trademark of Baxalta Incorporated.
FIRAZYR® and the FIRAZYR Logo are registered trademarks of Shire Orphan Therapies GmbH.
FOSRENOL® and the FOSRENOL Logo are registered trademarks of Shire International Licensing BV, a Takeda company.
FRUZAQLATM and the FRUZAQLA Logo are trademarks of HUTCHMED Group Enterprises Limited, used under license.
GAMMAGARD® and GAMMAGARD LIQUID® are registered trademarks of Baxalta Incorporated.
GLASSIA® is a registered trademark used under license from Kamada Ltd.
HyQvia® is a registered trademark of Baxalta Incorporated.
IMMUNINE® is a registered trademark of Baxalta Incorporated.
INTUNIV XR® is a registered trademark of Takeda Pharmaceuticals U.S.A., Inc.
KAZANO® is a registered trademark of Takeda Pharmaceutical Company Limited.
LIVTENCITY® and the LIVTENCITY Logo® are registered trademarks of Takeda Pharmaceuticals International AG.
MEZAVANT® and the MEZAVANT Logo® are registered trademarks of Nogra Pharma Limited, used under license.
NESINA® is a registered trademark of Takeda Pharmaceutical Company Limited.
NINLARO® is a registered trademark of Millennium Pharmaceuticals, Inc.
OBIZUR® is a registered trademark of Baxalta Incorporated.
ONDISSOLVE® is a registered trademark of Takeda GmbH.
PANTOLOC® and TECTA® are registered trademarks of Takeda GmbH. Used under licence.
REPLAGAL® and the REPLAGAL Logo® are registered trademarks of Shire Human Genetic Therapies, Inc.
REVESTIVE® is a registered trademark of Shire-NPS Pharmaceuticals, Inc., a Takeda company.
RIXUBIS® and BAXJECT® II are registered trademarks of Baxalta Incorporated.
TAKHZYRO® is a registered trademark of Dyax Corp.
ULORIC® is a registered trademark of Teijin Limited and used under licence by Takeda Canada Inc.
VONVENDI® is a registered trademark of Baxalta Incorporated.
VPRIV® and the VPRIV Logo® are registered trademarks of Shire Human Genetic Therapies, Inc.